Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life.

Interestingly, we observed that, just as for 6E10 and WO2 APP/Aβ antibodies, the immunoreactivity levels of 1 mer 4 KDa detected both Aβ-specific antibodies were higher in 12 A12 mAb-treated Tg2576 in comparison to their not-immunized counterpart (one-way ANOVA followed by Bonferroni’s post-hoc test; **** p < 0.0001 Tg2576 + mAb versus Tg2576) but that the trend of D8Q7I did not reach statistical significance (ns = not significant), suggesting that the largest part of soluble Aβ species present into animals’ hippocampi following treatment 12 A12 mAb is more likely to consist of monomeric Aβ42 peptide.

also in 111,027 other papers